Tilray Medical, a division of Tilray Brands, Inc. ("Tilray")
(Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis,
empowering the therapeutic alliance between patients and healthcare
practitioners to make informed individualized health decisions,
transforming healthcare, today announced a new Tilray led
scientific publication, Age-related Patterns of medical Cannabis
Use: A Survey of Authorized Patients in Canada. The new study was
derived from the Canadian Cannabis Patient Survey (CCPS) 2021,
comprised of 2,697 patients and focused primarily on older patients
with a mean age of 54.3. This study presents to the medical and
scientific community the consumption trends observed in patients
and the self-reported impacts from medical cannabis in alleviating
the patients’ primary symptoms.
The Age-related Patterns of Medical
Cannabis Use study finds that older
patients comprise a growing subset of medical cannabis patients.
The primary illnesses and symptoms for which medical cannabis was
sought after by patients in this study were chronic pain (27.8%)
and arthritis (14.9%) as the most common primary illnesses, pain as
the most common primary symptom (66%), anxiety (9%) as the third
most primary illness and second most primary symptom, and
insomnia/sleep disorder as a common symptom co-morbid with chronic
pain and other illnesses reported by 34.6%. Among patients taking
prescription opioids, 53.8% reported a decrease in use over the
past year with medical cannabis. Study participants reported that
cannabis had a high degree of efficacy in alleviating their illness
or symptoms, and many reported a reduction in their use of
prescription opioids, alcohol, tobacco, and other substances.
José Tempero, Tilray’s Medical Director, said,
"Our role in this initiative exemplifies our commitment to medical
research, leading us one step closer to unlocking the full
therapeutic potential of medical cannabis."
Tilray Medical’s mission is to continue
transforming lives and fostering dignity for patients in need
through access to medical cannabis, and today is a leading provider
of EU-GMP certified medical cannabis products in over 20 countries
with a comprehensive portfolio of THC and CBD products. Tilray has
supported medical trials globally, across Europe, Canada, the
United States, Australia, and Latin America, studying the efficacy
of medical cannabis as a treatment for indications including
pediatric epilepsy, refractory pediatric epilepsy, cancer-induced
nausea and vomiting, HIV, essential tremor, breast cancer
disorders, post-traumatic stress disorder, and alcohol use
disorders.
About Tilray
Medical Tilray Medical is dedicated to transforming
lives and fostering dignity for patients in need through safe and
reliable access to a global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray
grew from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the
first GMP-certified cannabis production facilities in Europe, first
in Portugal and later in Germany. Today, Tilray Medical is one of
the largest suppliers of medical cannabis to patients, physicians,
hospitals, pharmacies, researchers, and governments, in 20
countries and across five continents.
For more information on Tilray Medical, visit
Tilray Medical Europe, Tilray Medical Canada, and Tilray
Medical Australia-New Zealand.
About Tilray BrandsTilray
Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global
cannabis-lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is changing people's lives for the better – one
person at a time. Tilray Brands delivers on this mission by
inspiring and empowering the worldwide community to live their very
best life and providing access to products that meet the needs of
their mind, body, and soul while invoking wellbeing. Patients and
consumers trust Tilray Brands to deliver a cultivated experience
and health and wellbeing through high-quality, differentiated
brands and innovative products. A pioneer in cannabis research,
cultivation, and distribution, Tilray’s unprecedented production
platform supports over 20 brands in over 20 countries, including
comprehensive cannabis offerings, hemp-based foods, and craft
beverages.
For more information on how we open a world of wellbeing,
visit www.Tilray.com.
Forward-Looking
Statements Certain statements in this communication
that are not historical facts constitute forward-looking
information or forward-looking statements (together,
“forward-looking statements”) under Canadian and U.S. securities
laws and within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, that are intended to be subject to the “safe
harbor” created by those sections and other applicable laws.
Forward-looking statements can be identified by words such as
“forecast,” “future,” “should,” “could,” “enable,” “potential,”
“contemplate,” “believe,” “anticipate,” “estimate,” “plan,”
“expect,” “intend,” “may,” “project,” “will,” “would” and the
negative of these terms or similar expressions, although not all
forward-looking statements contain these identifying words. Certain
material factors, estimates, goals, projections, or assumptions
were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations. Many factors could cause actual results, performance,
or achievement to be materially different from any forward-looking
statements, and other risks and uncertainties not presently known
to the Company or that the Company deems immaterial could also
cause actual results or events to differ materially from those
expressed in the forward-looking statements contained herein. For a
more detailed discussion of these risks and other factors, see the
most recently filed annual information form of Tilray and the
Annual Report on Form 10-K (and other periodic reports filed with
the SEC) of Tilray made with the SEC and available on EDGAR. The
forward-looking statements included in this communication are made
as of the date of this communication and the Company does not
undertake any obligation to publicly update such forward-looking
statements to reflect new information, subsequent events, or
otherwise unless required by applicable securities laws.
Contacts:
Tilray Brands:Berrin Nooratanews@tilray.com
InvestorsRaphael
Gross203-682-8253Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024